News and Trends 29 Oct 2019
MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II
Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing…